Our pipeline

立博客户端app下载有一个令人兴奋和平衡的管道,以伟大的科学为基础.

Home / Our therapy areas / Our pipeline

Latest quarterly updates

立博客户端app下载的产品线在临床开发的不同阶段形成了强大的研究性治疗组合.


182

projects in our pipeline

19

new molecular entities in our late-stage pipeline

2

new molecular entities under review

第三阶段/LCM项目:指的是第二/第三阶段的关键资产, or that have been submitted for regulatory approval, 并且可能包括现在在一个或多个主要市场推出的资产(在所有适用的主要市场推出时删除).


Oncology (as of 25 April 2024)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects

心血管、肾脏和代谢(截至2024年4月25日)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects

Respiratory & Immunology (as of 25 April 2024)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects

Rare Disease (as of 25 April 2024)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects

Vaccine & Immune therapies (as of 25 April 2024)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects

Other (as of 25 April 2024)

Phase I

Phase I

Phase II

Phase II

Phase III

Phase III

LCM Projects

LCM Projects

Removed since last quarter

Veeva ID: Z4-57208
Date of preparation: August 2023